Basal Insulin Strategies Before Surgery

Status Completed

Clinical Trial Summary

Many patients with Type 2 Diabetes Mellitus (T2DM) are currently being managed with Basal Insulin (BI). However, there is little evidence to support guidelines on dosing adjustments in the preoperative period. The Society for Ambulatory Anesthesia does not advise a reduction in the dose of BI preoperatively, unless there is a specific history of hypoglycemia. The Endocrine Society suggests a 50% reduction in BI dose the evening before surgery. The authors hypothesized that a 25% reduction in BI dose the evening before surgery will result in better perioperative blood glucose control compared with our institutional 50% decrease.

Clinical Trial Description

A total of 40 subjects diagnosed with T2DM taking once-daily evening BI, scheduled to undergo elective surgery under general anesthesia will be consented and randomized in a 1:1 ratio to received either 50% or 25% reduction of their regular evening BI dose on the evening before surgery. Blood glucose levels (BGL) will be recorded perioperatively according to institutional guidelines. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03104738
Study type	Interventional
Source	Ohio State University
Contact
Status	Completed
Phase	N/A
Start date	November 20, 2013
Completion date	August 18, 2016

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04082091` - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Active, not recruiting	`NCT02248311` - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population	N/A
Completed	`NCT02653300` - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)	Phase 2
Completed	`NCT03655535` - Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes	Phase 2
Completed	`NCT03256747` - Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes	N/A
Completed	`NCT05343767` - Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus	N/A
Withdrawn	`NCT03675074` - Neujia Anastomosis for Treatment of Obesity and Type II Diabetes	N/A
Withdrawn	`NCT03190798` - Effects of Canagliflozin on Intravascular Volume and Hemodynamics	Phase 4
Withdrawn	`NCT03437330` - Empagliflozin Effect on Glucose Toxicity	Phase 4
Withdrawn	`NCT03008395` - Empowerment, Motivation and Medical Adherence (EMMA).	N/A
Not yet recruiting	`NCT05539066` - AI Health Assistant and Type 2 Diabetes	N/A
Completed	`NCT03682445` - Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus	N/A
Not yet recruiting	`NCT03239119` - The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus	Phase 3
Completed	`NCT03259789` - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects	Phase 3
Recruiting	`NCT03506230` - Financial Incentives for Low Socioeconomic Diabetic Patients	N/A
Completed	`NCT03072407` - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM	Phase 1
Completed	`NCT05668442` - Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
Completed	`NCT02956044` - Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin	Phase 1
Completed	`NCT02964572` - Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes	N/A
Completed	`NCT02628392` - A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)	N/A